Hyperlipidemia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Hyperlipidemia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Hyperlipidemia Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Hyperlipidemia, historical and forecasted epidemiology as well as the Hyperlipidemia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Hyperlipidemia Market by downloading the comprehensive report from DelveInsight @ Hyperlipidemia Drugs Market Landscape

 

Key Takeaways from the Hyperlipidemia Market Report

• In September 2024:- Novartis Pharmaceuticals-This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to
• In September 2024:- Merck Sharp & Dohme LLC- This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
• According to data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018, the prevalence of hypercholesterolemia (total cholesterol ≥ 240 mg/dL) was found to be 11.5%, translating to an estimated 12.05 million Americans. Additionally, the prevalence of hypertriglyceridemia (triglyceride levels ≥ 200 mg/dL) was reported at 10.4%, or about 10.84 million Americans.
• As per the research by Ramírez et al. (2020), 33.8% of the population presented any of the forms of hyperlipidemias, being more frequent in men (50.6%) than in women (28.8%).
• As per our analysis, primary hyperlipidemia is more prevalent in the US compared to Japan, with the US showing a higher proportion of individuals affected due to genetic factors and broader diagnostic efforts.
• As per our analysis, the prevalence of hyperlipidemia in the US varies significantly by age group. It is rare in children under two years, but may occur if they are underweight or obese, resulting in secondary pediatric hyperlipidemia. Among young adults (20-39), 11.3% are affected, reflecting relatively lower risk. Prevalence increases to 15.1% in middle-aged adults (40-59) due to lifestyle and metabolic factors. In older adults (60+), 76% are affected, with many remaining undiagnosed or untreated.
• The leading Hyperlipidemia Companies such as Novartis Pharmaceuticals, Beijing Suncadia Pharmaceuticals Co., Ltd, NewAmsterdam Pharma, Daewoong Pharmaceutical Co. LTD., Hasten Biopharmaceutical Co., Ltd., Arrowhead Pharmaceuticals, Visirna Therapeutics HK Limited, Ionis Pharmaceuticals, Inc., and others.
• Promising Hyperlipidemia Therapies such as Pelacarsen (TQJ230) 80 mg s.c., SHR-1918, Evolocumab, Statins (Cardiovascular Agents), Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg, and others.

 

Gain a competitive edge in the Hyperlipidemia Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Hyperlipidemia Treatment Drugs

 

Hyperlipidemia Epidemiology Segmentation in the 7MM

• Hyperlipidemia Diagnosed Prevalent Cases
• Hyperlipidemia Etiology-specific Diagnosed Prevalent Cases
• Hyperlipidemia Gender-specific Diagnosed Prevalent Cases
• Hyperlipidemia Age-specific Diagnosed Prevalent Cases

 

Hyperlipidemia Market Insights

Hyperlipidemia is a medical term for abnormally high levels of fats (lipids) in the blood, which include cholesterol and triglycerides. Although hyperlipidemia can be inherited, it’s most often the result of lifestyle factors, including an unbalanced diet and too little physical activity. If lifestyle changes aren’t enough to treat hyperlipidemia, doctor may prescribe medication.

 

Discover key developments and opportunities in the Hyperlipidemia Market. Click here to learn more from DelveInsight’s latest report @ Hyperlipidemia Market Size

 

Hyperlipidemia Treatment Market

The hyperlipidemia treatment market has experienced steady growth, attributed to rising rates of obesity, sedentary lifestyles, and unhealthy dietary habits, all of which contribute to higher lipid levels in the population. Additionally, the aging population is at a higher risk for hyperlipidemia, further driving the demand for effective treatments. According to market analysis, the demand for hyperlipidemia therapies is expected to increase as patients and healthcare providers emphasize early diagnosis and management to prevent long-term complications.

 

Hyperlipidemia Emerging Drugs

• SLN360: Silence Therapeutics plc
• VERVE-101 and VERVE-102: Verve Therapeutics, Inc.

 

Hyperlipidemia Market Driver

The rising incidence of hyperlipidemia, particularly due to sedentary lifestyles, poor dietary habits, and the growing rate of obesity, is a major driver for market growth. Hyperlipidemia has become a common metabolic disorder across the globe, leading to a surge in demand for effective treatments.

 

Hyperlipidemia Market Barrier

The cost of newer lipid-lowering therapies, such as PCSK9 inhibitors, can be prohibitive for many patients, especially in low- and middle-income countries. This high cost can limit patient access to these advanced treatments and act as a barrier to market growth.

 

Download DelveInsight’s Hyperlipidemia Market report today and stay ahead in this rapidly evolving field. @ Hyperlipidemia Clinical Trials

 

Scope of the Hyperlipidemia Market Report

• Coverage- 7MM
• Hyperlipidemia Companies- Novartis Pharmaceuticals, Beijing Suncadia Pharmaceuticals Co., Ltd, NewAmsterdam Pharma, Daewoong Pharmaceutical Co. LTD., Hasten Biopharmaceutical Co., Ltd., Arrowhead Pharmaceuticals, Visirna Therapeutics HK Limited, Ionis Pharmaceuticals, Inc., and others.
• Hyperlipidemia Therapies- Pelacarsen (TQJ230) 80 mg s.c., SHR-1918, Evolocumab, Statins (Cardiovascular Agents), Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg, and others.
• Hyperlipidemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Hyperlipidemia Unmet Needs, KOL’s views, Analyst’s views, Hyperlipidemia Market Access and Reimbursement

 

Download the report to understand which factors are driving Hyperlipidemia Market Trends @ Hyperlipidemia Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Hyperlipidemia

3. Competitive Intelligence Analysis for Hyperlipidemia

4. Hyperlipidemia: Market Overview at a Glance

5. Hyperlipidemia: Disease Background and Overview

6. Patient Journey

7. Hyperlipidemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperlipidemia Unmet Needs

10. Key Endpoints of Hyperlipidemia Treatment

11. Hyperlipidemia Marketed Products

12. Hyperlipidemia Emerging Therapies

13. Hyperlipidemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hyperlipidemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/